KLK7

Kallikrein-7

48,822 patent compounds predicted against KLK7, 25,470 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL361290	0.54	11/20
SCHEMBL361291	0.54	11/20
SCHEMBL317876	0.64	9/20
SCHEMBL360673	0.59	9/20
SCHEMBL360674	0.59	9/20
SCHEMBL360652	0.68	8/20
SCHEMBL360653	0.68	8/20
SCHEMBL359759	0.57	8/20
SCHEMBL359760	0.57	8/20
SCHEMBL247530	0.54	8/20
SCHEMBL360231	0.54	7/20
SCHEMBL360232	0.54	7/20
SCHEMBL279567	0.43	7/20
SCHEMBL360678	0.66	6/20
SCHEMBL360679	0.66	6/20
SCHEMBL759185	0.47	6/20
SCHEMBL582271	0.45	6/20
SCHEMBL433353	0.42	6/20
SCHEMBL85867	0.55	5/20
SCHEMBL54187	0.51	5/20

Germline variants in KLK7 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full KLK7 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to KLK7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism	PHASE4	COMPLETED
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II	PHASE3	COMPLETED
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema	PHASE3	COMPLETED
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer	PHASE2	COMPLETED
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA	PHASE1/PHASE2	RECRUITING
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer	PHASE2	COMPLETED
Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer	PHASE2	COMPLETED
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery	PHASE1/PHASE2	COMPLETED
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer	PHASE2	COMPLETED
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke	PHASE2	COMPLETED
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies	PHASE1/PHASE2	UNKNOWN
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.	PHASE2	WITHDRAWN
Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen	PHASE2	COMPLETED
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy	PHASE2	RECRUITING
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide	PHASE2	UNKNOWN
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME	PHASE1	COMPLETED
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.	PHASE1	COMPLETED
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy	EARLY_PHASE1	NOT_YET_RECRUITING
Urinary Kallikrein and Hypertension: A Prospective Study	nan	COMPLETED
The Contact Activation System and Ulcerative Colitis	nan	COMPLETED
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion	nan	RECRUITING
A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland	nan	UNKNOWN
Predicting Prostate Biopsy Results With Biomarkers and mpMRI.	nan	COMPLETED
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer	nan	COMPLETED
Can Nephrocheck™ Predict the Reversibility of Early, Acute Kidney Injury During Septic Shock?	nan	COMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia	nan	COMPLETED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer	nan	UNKNOWN
A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KLK7 binder may also engage these)

Protein	Name	Similarity
P09582	—	0.987	P09582 →
KLK3	Prostate-specific antigen	0.987	landscape →
Q91VE3	—	0.987	Q91VE3 →
KLK2	Kallikrein-2	0.984	landscape →
Q07276	—	0.984	Q07276 →
Q28773	—	0.983	Q28773 →
P56435	—	0.983	P56435 →
P33619	—	0.983	P33619 →
P50341	—	0.983	P50341 →
P09650	—	0.982	P09650 →
Q03238	—	0.982	Q03238 →
KLK6	Kallikrein-6	0.982	landscape →
Q00356	—	0.981	Q00356 →
CMA1	Chymase	0.981	landscape →
KLK13	Kallikrein-13	0.981	landscape →
Q76B45	—	0.981	Q76B45 →
O46683	—	0.981	O46683 →
P21812	—	0.980	P21812 →
KLK5	Kallikrein-5	0.980	landscape →
P36369	—	0.980	P36369 →
Q6DT45	—	0.980	Q6DT45 →
P97592	—	0.980	P97592 →
KLK1	Kallikrein-1	0.980	landscape →
P50339	—	0.979	P50339 →
P50342	—	0.978	P50342 →
P21844	—	0.978	P21844 →
P36368	—	0.978	P36368 →
A7WPL7	—	0.978	A7WPL7 →
O35205	—	0.978	O35205 →
P80219	—	0.978	P80219 →